FOLH1 and neoplasm: The anti-PSCA mAb 7F5 can be successfully radiolabeled with 177Lu resulting in a promising tool for imaging and potentially for therapeutic targeting of PSCA positive tumor entities including, for example, PSMA-negative PCas.